Candel Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Paul-Peter Tak
- Full Time Employees
- 38
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 117 Kendrick Street Needham MA United States of America 02494
- IPO Date
- Jul 27, 2021
- CIK
- 0001841387
- Website
- candeltx.com
- Similar Companies
- Business
- Candel Therapeutics, Inc. (NASDAQ: CADL) is a clinical-stage biopharmaceutical company that develops off-the-shelf viral immunotherapies designed to elicit individualized, systemic antitumor immune responses to treat solid tumors. The company's lead product candidate, CAN-2409 (adenovirovec), an investigational multimodal biological immunotherapy from its adenovirus platform, is advancing in a completed Phase 3 trial under FDA Special Protocol Assessment for intermediate-to-high-risk localized prostate cancer, where it has received Regenerative Medicine Advanced Therapy and Fast Track designations; ongoing Phase 2 trials in non-small cell lung cancer (NSCLC) and borderline resectable pancreatic ductal adenocarcinoma (PDAC), with Fast Track and Orphan Drug designations for PDAC, respectively; and positive topline overall survival data from Phase 2a trials in both NSCLC and PDAC. CAN-3110, the lead candidate from its herpes simplex virus (HSV) platform, targets recurrent high-grade glioma in a Phase 1b trial. The enLIGHTEN Discovery Platform further supports development of novel HSV-based viral immunotherapies for additional solid tumors through systematic engineering leveraging human biology and advanced analytics. Founded in 2003 and formerly known as Advantagene, Inc. until its name change in November 2020, Candel Therapeutics is headquartered at 117 Kendrick Street, Suite 450, Needham, Massachusetts. In October 2025, the company entered a $130 million term loan facility with Trinity Capital Inc., drawing down $50 million initially to bolster its cash position to $137.2 million pro forma as of September 30, 2025, funding pivotal Phase 3 initiation for CAN-2409 in NSCLC in Q2 2026, BLA preparations for prostate cancer, and pre-commercial activities pending approval. Candel concurrently prioritized its portfolio by focusing internal resources on prostate cancer and NSCLC programs while pursuing externally funded partnerships for CAN-2409 in PDAC, following compelling Phase 2a data and positive regulatory feedback. The company also completed patient enrollment and reported positive pivotal topline Phase 3 data for CAN-2409 in prostate cancer, positioning it for BLA submission.
Candel Therapeutics: An Overlooked Late-Stage Biotech With Real Potential
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer
Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Candel Therapeutics Eyes Year-End BLA After Strong Prostate Cancer Data
Wall Street Analysts Believe Candel Therapeutics (CADL) Could Rally 148.48%: Here's is How to Trade
Candel Therapeutics, Inc. (CADL) Discusses Extended Follow-Up Data From Phase 3 Trial of aglatimagene besadenovec in Localized Prostate Cancer Transcript
Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting
Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Candel Therapeutics to Present at Upcoming Investor Conferences
Candel Therapeutics to Present at Upcoming Investor Conferences
Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fed holds rates, but rare split exposes deepening divide
Candel Therapeutics teams up with EVERSANA to prep for prostate cancer drug launch